• Fidelity National Information Services, Inc. recently reported first‑quarter 2026 results with revenue rising to US$3.30 billion and net income jumping to US$2.37 billion, while also unveiling new AI and digital-money initiatives for bank clients.
• A key development is FIS’s collaboration with Anthropic on an AI-driven Financial Crimes Agent and the launch of its Lyriq and Project Keystone platforms, signaling an effort to embed advanced AI and tokenized deposit infrastructure directly into regulated banking workflows.
• We’ll now examine how FIS’s Anthropic AI partnership and broader digital-money initiatives may influence the company’s existing investment narrative.

Invest in the nuclear renaissance through our list of 91 elite nuclear energy infrastructure plays powering the global AI revolution.

Fidelity National Information Services Investment Narrative Recap

To own FIS, you need to believe that its core banking and payments platforms, combined with new AI and digital‑money offerings, can deepen its role inside large financial institutions. The immediate catalyst is management proving that recent deals and new products can translate into sustainable, high quality earnings after a quarter boosted by the Worldpay stake sale. A key risk remains integration and execution across acquisitions and new platforms, especially given FIS’s high debt load.

The Anthropic partnership around the Financial Crimes AI Agent is most relevant here, because it directly targets one of FIS’s biggest short term catalysts: selling higher value AI tools into its existing bank base. If FIS can turn this first agent into a repeatable template for credit, onboarding and fraud products, it could reinforce its “system of record plus AI” story and potentially offset pressure from fintech competitors and changing client buying patterns.

Yet while the headlines look positive, investors should be aware that execution missteps in integrating the issuer acquisition and scaling these AI and digital‑money platforms could...

Fidelity National Information Services' narrative projects $15.0 billion revenue and $2.4 billion earnings by 2029. This requires 12.1% yearly revenue growth and about a $2.0 billion earnings increase from $382.0 million today.

Uncover how Fidelity National Information Services' forecasts yield a $65.29 fair value, a 38% upside to its current price.

Exploring Other Perspectives

Before this news, the most optimistic analysts were assuming FIS could lift annual revenue growth to about 13% and earnings to roughly US$2.6 billion, but if banks prefer third party AI layers instead of FIS’s own tools, that AI powered margin story could look very different, so it is worth comparing how your view lines up with both these bullish assumptions and the more cautious consensus.

Explore 3 other fair value estimates on Fidelity National Information Services - why the stock might be worth just $58.60!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Fidelity National Information Services research is our analysis highlighting 2 key rewards and 4 important warning signs that could impact your investment decision.
• Our free Fidelity National Information Services research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Fidelity National Information Services' overall financial health at a glance.

Looking For Alternative Opportunities?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• We've uncovered the 12 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Explore 27 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• AI is about to change healthcare. These 35 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.